Avelox® Monotherapy Shows Strong Performance In Treating Hospitalized Pneumonia Patients
A recently published study in Clinical Infectious Diseases shows that Avelox® (moxifloxacin HCl) monotherapy is as powerful as a high dose combination regimen of ceftriaxon plus levofloxacin in the treatment of hospitalised patients with community-acquired pneumonia (CAP). A total of 569 patients at 69 centres in 17 countries from Southern and Northern Europe, Latin America and South Africa were treated in the MOTIV(1) trial (MOxifloxacin Treatment IV).
More: continued here
Filed under: Infectious Diseases / Bacteria / Viruses on May 22nd, 2008